SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Iota Variant

Reference:
Product nameSARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Iota Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /Synonymslineage B.1.526, New Yorker variant, Nyvariant, Iota variant
ReferencePX-COV-P058
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Variant – Iota Variant

During the last quarter of 2020, investigators have witnessed the rise of several variants carrying multiple mutations with biological significance. Many of these biologically relevant mutations are focused on the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2. Residues that are responsible for binding the human receptor ACE2 or those that are bound by neutralizing antibodies are the ones suffering the most changes.
In November 2020, a new lineage of SARS-CoV-2 was detected in the state of New York (USA) by researchers from Caltech and Columbia University. The most common set of mutations found in the spike protein of the new lineage – B.1.526 – are L5F, T95I, D253G, E484K or S477N (never the two at the same time), D614G, and A701V. The relative abundance of this lineage in the NY area has reached 25% in February 2021, representing a 26-fold increase in a little over a month. Its frequency is expected to keep rising in the months to come.
Mutation E484K is shared with lineages B.1.351 (South Africa) and P.1 (Brazil) and suspected to increase SARS-CoV-2’s ability to evade the immune system by reducing the potency of class 1 antibodies that target this region. Mutation S477N has also been detected in other lineages of SARS-CoV-2, but this is the first time a lineage carrying it becomes so abundance in the circulating SARS-CoV-2 population. This mutation may be associated with an increased affinity towards the human ACE2 receptor and increased resistance to SARS-CoV-2 neutralizing antibodies.
The fact that this is the first time we are seeing a steady increase of viruses carrying the S477N mutation can be explained by its association with the D253G, adjacent to the RBD. This mutation falls into the loop of the N-terminal domain (NTD) of the spike. For this reason, it is expected to abolish an important neutralizing epitope in this region and contribute to increased immune resistance. The combination of E484K or S477N with D253G may exacerbate SARS-CoV-2 infectivity and contribute to a new surge of COVID-19 cases worldwide.
This RBD fragment contains the S477N mutation found in lineage B.1.526. For the variant carrying the E484K mutation, click here.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Iota Variant”

Your email address will not be published. Required fields are marked *

Related products

Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031-SIL 1500€
Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032-SIL 1500€
Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Stable Istotope Labelled Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033-SIL 1500€
Stable Isotope Labeled Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Stable Isotope Labeled Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637-SIL 1500€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 230€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.